ライフサイエンスコーパス: douche

1 ch received 660 mg of TFV in a 125-mL rectal douche.

2 hed in every study interval, and 43.0% never douched.

3 risk of bacterial vaginosis associated with douching.

4 number of sex partners, age of partner, and douching.

5 Three tenofovir rectal douches-220 mg iso-osmolar product A, 660 mg iso-osmolar

6 All 3 tenofovir douches achieved tissue tenofovir-diphosphate concentrat

7 Colorectal distribution of both douche and HIV surrogate radioisotopes were assessed usi

8 onsidered scenarios, 41%-64% of participants douched and 35%-56% used genital talc.

9 short bursts of a nasal decongestant, saline douches and nasal anticholinergics.

10 e data do not support an association between douching and development of PID or gonococcal/chlamydial

11 varian cancer (HR range, 1.17-3.34) Frequent douching and douching during young adulthood were positi

12 ave examined the association between vaginal douching and genital human papillomavirus (HPV) infectio

13 The observed positive association between douching and incident cervical cancer is consistent with

14 We investigated the associations between douching and numbers of HPV genotypes infecting 1271 par

15 Associations between douching and PID or gonococcal/chlamydial genital infect

16 to modifications of maternal behavioral (ie, douching and smoking) and biological traits (ie, body ma

17 Candidates include douching and talcum powder applied in the genital area.

18 (AOR = 4.18, 95% CI: 1.78-9.80) and vaginal douching (AOR = 5.48, 95% CI: 2.39-12.56) were significa

19 (AOR = 9.47, 95% CI: 4.09-21.94) and vaginal douching (AOR = 6.93, 95% CI: 2.86-16.77).

20 ven, behaviorally congruent rectal tenofovir douche as a PrEP option for RAI and demonstrated product

21 The relative risk for regular douching as compared with no douching was 1.21 (95% conf

22 Douching at ages 10-13 was positively associated with pr

23 Clinically, vaginal-douche BD2 concentrations were reduced (p < 0.05) in wom

24 A tenofovir-medicated rectal douche before receptive anal intercourse may provide thi

25 i decreased IL6 production in the absence of douches, but increased IL6 production after exposure to

26 ical tar exposures through tar-based vaginal douching, cigarette smoking, and/or long-term cooking ov

27 These findings indicate that douching confers increased risk of disruption of vaginal

28 Risks for redetection included douching, current use of medroxyprogesterone, reporting

29 (HR range, 1.17-3.34) Frequent douching and douching during young adulthood were positively associat

30 Douching following RAI may increase HIV distribution in

31 f a novel tenofovir (TFV) rectal microbicide douche for HIV prevention.

32 ew sex partner (HR = 2.5, P = .004) and with douching for hygiene (HR = 2.1, P = .05).

33 ariate logistic regression demonstrated that douching >/=2 times during the past month (odds ratio [O

34 ization is influenced by sexual activity and douching habits.

35 The douches had high acceptability without toxicity.

36 Douching has been linked to gonococcal or chlamydial cer

37 Vaginal douching has been reported to be associated with bacteri

38 Frequency of douching immediately preceding PID or gonococcal/chlamyd

39 Thirty-two percent of participants douched in every study interval, and 43.0% never douched

40 by indication--that is, confounding by women douching in response to vaginal symptoms associated with

41 After controlling for relevant covariates, douching in the past 6 months was significantly associat

42 Douching in the year before enrollment was positively as

43 Tenofovir douches may provide a single-dose, on-demand, behavioral

44 Neither recent douching nor sexual practices with male partners were as

45 associated with ovarian cancer, but neither douching nor talc was associated with breast or uterine

46 al modeling to estimate the causal effect of douching on bacterial vaginosis risk while controlling f

47 ciation with cervicitis was seen for current douching or smoking, race, time since or frequency of in

48 gate and tenofovir douche when the tenofovir douche preceded or followed simulated RAI (sRAI).

49 etriaminepentaacetic acid-labelled tenofovir douche prior to sRAI using 99mTc-sulfur colloid in autol

50 All studied douching products (vinegar, iodine and baking soda based

51 Douching products may be associated with epithelial disr

52 We compared the effect of commercial vaginal douching products on Lactobacillus crispatus, L. jenseni

53 ctobacilli immediately following exposure to douching products resulted in a trend to less human cell

54 ower IL1RA regardless of presence or type of douching solution.

55 After adjustment for confounding factors, douching two or more times per month at baseline was ass

56 At visit two, the radiolabeled tenofovir douche was administered following radiolabeled sRAI.

57 tion extended into descending colon when the douche was administered following sRAI.

58 rrogate was within the rectosigmoid when the douche was administered prior to sRAI, but the distribut

59 Colorectal distribution of the douche was not different between sequences.

60 The TFV rectal douche was safe, well tolerated, and acceptable to YMSM.

61 isk for regular douching as compared with no douching was 1.21 (95% confidence interval: 1.08, 1.38).

62 Data on genital talc use and douching were collected at enrollment and follow-up.

63 r miscarriage, smoking, menstrual cycle, and douching were positively associated with M. genitalium,

64 stribution of an HIV surrogate and tenofovir douche when the tenofovir douche preceded or followed si

65 BV was common among subjects who did not douche, who did not have concurrent sex with male partne